U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT06904261) titled 'A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) with Fabry Disease and Amenable GLA Variants' on March 13.
Brief Summary: An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to < 12 years of age with Fabry disease and with amenable GLA variants.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Fabry Disease
Intervention:
DRUG: Migalastat HCl 20 mg
Migalastat will be supplied as 20-mg dispersible tablets. Migalastat 20-mg dispersible tablets contain 16 mg migalastat free base.
Recruitment Status: NOT_...